肝细胞腺瘤肝胆期摄取肝特异性MR对比剂可作为显著β-catenin激活的生物标志物
该多中心回顾性研究纳入124个病理证实的肝细胞腺瘤,评估肝胆期肝特异性MR对比剂摄取预测显著β-catenin激活的价值。视觉分析将肿瘤分为低信号、等信号和高信号,高信号组中44%为β-catenin激活型;病灶-肝脏对比增强率(LLCER)≥0%诊断显著β-catenin激活的敏感度为75%、特异度为97%,阳性似然比28。
要点
- 肝胆期病灶高信号者中44%为显著β-catenin激活型肝细胞腺瘤,等信号者25%,低信号者仅1%。
- LLCER≥0%诊断显著β-catenin激活的敏感度75%、特异度97%、阳性似然比28。
- 肝胆期视觉分析特异度高但敏感度低于LLCER定量,尤其伴肝脂肪变者。
关键影像表现/征象
- 肝胆期视觉分析将94/124(76%)肝细胞腺瘤归为低信号、12/124(10%)为等信号、18/124(14%)为高信号。
- 低信号组中1/94(1%)为HCA B+,等信号组中3/12(25%)为HCA B+,高信号组中8/18(44%)为HCA B+(p < 0.001)。
- HCA B+的LLCER高于无显著β-catenin激活的肝细胞腺瘤(均值4.9 ± 11.8% vs. -19.8 ± 11.4%,p < 0.001)。
诊断标准与关键数值
- LLCER≥0%(即正LLCER)诊断HCA B+的敏感度为75%(95% CI 43-95%),特异度为97%(95% CI 92-99%),阳性似然比为28(95% CI 8.8-89.6)。
- 肝胆期视觉分析按病灶信号相对肝脏分为低信号、等信号、高信号三组。
临床应用与阅片要点
- 肝胆期视觉分析中病灶高信号或等信号提示可能存在显著β-catenin激活,低信号者该概率低(1%)。
- LLCER≥0%可作为提示显著β-catenin激活的定量指标,其特异度达97%。
- 视觉分析敏感度低于LLCER定量,尤以伴肝脂肪变的肝细胞腺瘤在肝胆期呈高信号者需注意。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess the value of hepatospecific MR contrast agent uptake on hepatobiliary phase (HBP) images to detect marked activation of the β-catenin pathway in hepatocellular adenomas (HCAs).
METHODS: This multicentric retrospective IRB-approved study included all patients with a pathologically proven HCA who underwent gadobenate dimeglumine-enhanced liver MRI with HBP. Tumor signal intensity on HBP was first assessed visually, and lesions were classified into three distinct groups-hypointense, isointense, or hyperintense-according to the relative signal intensity to liver. Uptake was then quantified using the lesion-to-liver contrast enhancement ratio (LLCER). Finally, the accuracy of HBP analysis in depicting marked β-catenin activation in HCA was evaluated.
RESULTS: A total of 124 HCAs were analyzed including 12 with marked β-catenin activation (HCA B+). Visual analysis classified 94/124 (76%), 12/124 (10%), and 18/124 (14%) HCAs as being hypointense, isointense, and hyperintense on HBP, respectively. Of these, 1/94 (1%), 3/12 (25%), and 8/18 (44%) were HCA B+, respectively (p < 0.001). The LLCER of HCA B+ was higher than that of HCA without marked β-catenin activation in the entire cohort (means 4.9 ± 11.8% vs. - 19.8 ± 11.4%, respectively, p < 0.001). A positive LLCER, i.e., LLCER ≥ 0%, had 75% (95% CI 43-95%) sensitivity and 97% (95% CI 92-99%) specificity, with a LR+ of 28 (95% CI 8.8-89.6) for the diagnosis of HCA B+.
CONCLUSIONS: Hepatospecific contrast uptake on hepatobiliary phase is strongly associated with marked activation of the β-catenin pathway in hepatocellular adenoma, and its use might improve hepatocellular adenoma subtyping on MRI.
KEY POINTS: • Tumor uptake on hepatobiliary phase in both the visual and quantitative analyses had a specificity higher than 90% for the detection of marked β-catenin activation in hepatocellular adenoma. • However, the sensitivity of visual analysis alone is inferior to that of LLCER quantification on HBP due to the high number of HCAs with signal hyperintensity on HBP, especially those developed on underlying liver steatosis.
引用
- Reizine E, Ronot M, Ghosn M, et al. Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma. Eur Radiol. 2020. PMID: 33146794. doi:10.1007/s00330-020-07434-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。